Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2014 by St. Jude Children's Research Hospital
Sponsor:
Collaborators:
University of Tennessee Health Science Center
University of Florida
Nemours Children's Clinic
Information provided by (Responsible Party):
St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier:
NCT01946529
First received: September 16, 2013
Last updated: June 9, 2014
Last verified: June 2014
  Purpose

This protocol will study treatment for Ewing sarcoma family of tumors (ESFT) and desmoplastic small round cell tumor (DSRCT). Participants with ESFT will be divided into two treatment groups, A or B, based on tumor characteristics.

Group A (standard risk) participants have tumor that is not in the pelvis, has not spread to other parts of the body, and are less than 14 years of age. Because previous clinical trials have shown that standard treatment is very effective for children whose tumors have these characteristics, these participants will receive standard treatment.

Group B (high risk) participants are 14 years of age or older or have tumor in the pelvis, or the tumor has spread to other parts of the body. Participants with DSRCT in the abdomen and/or pelvis or with tumor that cannot be removed by surgery alone or has spread to other parts of the body will be included in Group B. Participants in this group are considered high risk because there is a greater chance of tumor recurring following standard treatments currently in use.

All participants will be followed and evaluated for 10 years following completion of therapy.


Condition Intervention Phase
Desmoplastic Small Round Cell Tumor
Ewing Sarcoma of Bone or Soft Tissue
Localized Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Metastatic Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Drug: vincristine
Drug: doxorubicin
Drug: cyclophosphamide
Drug: ifosfamide
Drug: etoposide
Drug: temozolomide
Drug: temsirolimus
Drug: bevacizumab
Drug: sorafenib
Procedure: surgery
Radiation: radiation
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors

Resource links provided by NLM:


Further study details as provided by St. Jude Children's Research Hospital:

Primary Outcome Measures:
  • Response rate [ Time Frame: at 6 weeks after start of therapy (after 2 initial courses) ] [ Designated as safety issue: No ]
    Response rate will be defined as the proportion of patients who achieved complete response or partial response (CR+PR) using the World Health Organization (WHO) criteria evaluated after two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high risk ESFT. Participants who are treated in Group B with DSRCT or those who do not receive window therapy will not be included in this analysis.


Secondary Outcome Measures:
  • Overall Survival [ Time Frame: Maximum of 11 years after the start of therapy ] [ Designated as safety issue: No ]
    Overall survival (OS) is defined as the time interval from the date on study to the date of death or the date of last follow-up. OS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively.

  • Progression-free survival [ Time Frame: Maximum of 11 years after the start of therapy ] [ Designated as safety issue: No ]
    Progression free survival (PFS) is defined as the time interval from the date on study to the date of disease progression or death or the date if last follow-up. PFS will be estimated using the method of Kaplan-Meier for group A and B participants, respectively.

  • Time to progression [ Time Frame: Maximum of 11 years after the start of therapy ] [ Designated as safety issue: No ]
    Median time to progression of group B patients will be estimated from the Kaplan-Meier curve.

  • Local failure rate [ Time Frame: Maximum of 11 years after the start of therapy ] [ Designated as safety issue: No ]
    Loco-regional failure is defined as the time interval from date of start of local therapy to date of loco-regional failure. Distant failure or death prior to loco-regional failure will be considered competing events in the analyses. The cumulative incidence of loco-regional failure will be estimated using methods described in Kalbfleisch and Prentice.


Estimated Enrollment: 47
Study Start Date: November 2013
Estimated Study Completion Date: November 2029
Estimated Primary Completion Date: January 2019 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Group A (Standard Risk)
Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide and etoposide. Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone, or surgery followed by radiation. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.
Drug: vincristine
Dosage and route of administration: Infants < 12 months of age: 0.05 mg/kg IV day 1; participants ≥ 12 months of age: 1.5 mg/m^2 IV day 1 (max. dose 2 mg).
Other Name: Oncovin(R)
Drug: doxorubicin
Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2.
Other Name: Adriamycin(R)
Drug: cyclophosphamide
Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
Other Name: Cytoxan(R)
Drug: ifosfamide
Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5.
Other Name: Ifex(R)
Drug: etoposide
Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5.
Other Names:
  • VP-16
  • Vepesid(R)
Procedure: surgery
If participant meets the criteria, they will have surgical resection of their tumor.
Other Name: therapeutic conventional surgery
Radiation: radiation
If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
Other Names:
  • proton beam radiation therapy
  • external beam radiation therapy
  • brachytherapy
Active Comparator: Group B (High Risk)
Participants will receive vincristine, doxorubicin, cyclophosphamide, ifosfamide, etoposide, irinotecan, temozolomide, temsirolimus, bevacizumab, and sorafenib. Depending on the size and location of the participant's tumor, they will have surgery alone, radiation alone or surgery followed by radiation.
Drug: doxorubicin
Dosage and route of administration: Infants < 1 year 2.5 mg/kg continuous infusion (CI) over 48 hours, days 1-2; participants > 1 year of age 75 mg/m^2 CI over 48 hours, days 1-2.
Other Name: Adriamycin(R)
Drug: cyclophosphamide
Dosage and route of administration: The dose and route are different in neo-adjuvant/adjuvant chemotherapy and maintenance therapy. Please see the Detailed Description for further information.
Other Name: Cytoxan(R)
Drug: ifosfamide
Dosage and route of administration: Infants < 1 year of age 60 mg/kg/day IV over 60 minutes days 1-5; participants > 12 months of age 1800 mg/m^2 IV over 60 minutes x 5 days, days 1-5.
Other Name: Ifex(R)
Drug: etoposide
Dosage and route of administration: Infants < 1 year of age 3.3 mg/kg/day IV over 60 minutes days 1-5; children > 1 year 100 mg/m^2 daily IV over 60 minutes days 1-5.
Other Names:
  • VP-16
  • Vepesid(R)
Drug: temozolomide
Dosage and route of administration: Temozolomide 100 mg/m^2 PO once daily, days 1-5.
Other Name: Temodar(R)
Drug: temsirolimus
Dosage and route of administration: Temsirolimus 35 mg/m^2 IV once day 1 and day 8.
Other Names:
  • CCI-779
  • Torisel^TM
Drug: bevacizumab
Dosage and route of administration: Bevacizumab 15 mg/kg IV on day 1 every 3 weeks.
Other Names:
  • rhumab VEGF
  • Avastin(R)
Drug: sorafenib
Dosage and route of administration: 90 mg/m^2/dose PO BID
Other Names:
  • BAY-43-9006
  • Nexavar(R)
Procedure: surgery
If participant meets the criteria, they will have surgical resection of their tumor.
Other Name: therapeutic conventional surgery
Radiation: radiation
If the participant meets the criteria, participants will receive radiation therapy. Chemotherapy will continue during radiation.
Other Names:
  • proton beam radiation therapy
  • external beam radiation therapy
  • brachytherapy

Detailed Description:

PRIMARY OBJECTIVE:

  • To estimate the response rate to two initial courses of temsirolimus, temozolomide and irinotecan in previously untreated patients with high-risk Ewing sarcoma family of tumors (ESFT).

SECONDARY OBJECTIVES:

  • To estimate the overall survival and progression-free survival in participants with ESFT treated with these approaches.
  • To estimate the time to progression in participants with ESFT treated in Group B (high risk).
  • To estimate the cumulative incidence of local failure following local control paradigm in this trial.

Group A:

Participants will receive interval compressed (every 2 weeks) alternating courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC) and with ifosfamide and etoposide (IE). Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of chemotherapy. Total duration of treatment is approximately 29 weeks.

Group B:

Participants eligible for the window therapy will receive two courses (21 days duration each) of mTOR inhibitor, temsirolimus, in combination with temozolomide and irinotecan. Irinotecan (20 mg/m^2) will be administered IV on a protracted schedule of daily for 5 days, 2 days off, repeated daily x 5 [(qdx5)x2], temozolomide (100 mg/m^2) PO daily x 5 days and temsirolimus 35 mg/m^2 IV weekly on day 1 and 8. Following window treatment (weeks 1 - 6), participants will proceed to induction chemotherapy (weeks 7 - 33) consisting of interval compressed (every 2 weeks) alternating courses of chemotherapy with vincristine, doxorubicin, and cyclophosphamide (VDC) with ifosfamide and etoposide (IE). Doxorubicin will be omitted following a total cumulative dose of 375 mg/m^2. Local control measures (surgery and/or radiation therapy) will be instituted after 6 courses of induction chemotherapy (week 19). Participants whose tumors respond to window therapy will receive temsirolimus, temozolomide and irinotecan at weeks 29 and 31 in place of ifosfamide and etoposide. Following induction therapy, participants will receive six 21-day courses of maintenance therapy consisting of bevacizumab IV on day 1 and daily oral sorafenib and low-dose cyclophosphamide day 1 through day 21.

  Eligibility

Ages Eligible for Study:   up to 25 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Group A participants must be <14 years of age at time of diagnosis of histologically proven non-pelvic localized Ewing sarcoma family of tumor (ESFT) involving the bone or soft tissue.
  • Group B participants must have newly diagnosed of histologically proven ESFT involving the bone or soft tissue and at least one of the following: metastatic disease (must be biopsy proven), or pelvic primary, or ≥14 years of age at the time of diagnosis.
  • OR Group B participants must be newly diagnosed with intra-abdominal, unresectable or metastatic desmoplastic small round cell tumor. Metastatic site must be biopsy proven.
  • Age must be ≤25 years.
  • Adequate bone marrow function defined as a peripheral absolute neutrophil count (ANC) ≥750/m^3 and platelet count ≥75,000/m^3 (no transfusion within 7 days of study enrollment). Patients with Ewing sarcoma metastatic to the bone marrow are not required to meet bone marrow criteria for study eligibility and are not evaluable for hematologic toxicity.
  • Must have adequate renal function based on age.
  • Must not have had prior chemotherapy or radiation therapy. Emergent radiotherapy to preserve vital organ function is permitted. Participants who receive emergent radiation will not be eligible for window therapy.
  • Must have adequate hepatic function defined as total bilirubin ≤3.0 mg/dL.
  • Must have adequate cardiac function defined as shortening fraction ≥28%.
  • Females of childbearing potential and males able to father a child must be willing to practice acceptable methods of birth control to prevent pregnancy.
  • Additional criteria for Group B participants who will receive upfront window therapy (does not apply to participants who opt out of window therapy):

    • Cytochrome P450 CYP3A4 active agents: Must not be taking any of the following potent CYP3A4 inducers or inhibitors within 1 week prior to study entry: azole antifungals (such as fluconazole, voriconazole, itraconazole, ketoconazole), rifampin, phenytoin, phenobarbitol, carbamazepine, grapefruit juice and St. John's wort.
    • Must have measurable disease.
    • Must not have received emergent radiation therapy.
    • Serum triglyceride level ≤ 300 mg/dL and serum cholesterol ≤ 300 mg/dL.
    • Random or fasting glucose within the upper limits of normal for age. If random glucose is elevated, fasting glucose must be within normal range.
    • SGOT (AST) and SGPT (ALT) ≤3.0 x upper limit of normal for age.

Exclusion Criteria:

  • Participant is pregnant or breastfeeding.
  • Inability or unwillingness of research participant or legal guardian/representative to give written informed consent.
  • Participant has a prior history of malignancy, with the exception of non-melanoma skin cancer. Participants with history of skin cancer must have 5 years elapse since that diagnosis, be in remission, and must not have received chemotherapy, immunotherapy, or radiation therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01946529

Contacts
Contact: Fariba Navid, MD 866-278-5833 info@stjude.org

Locations
United States, Tennessee
St. Jude Children's Research Hospital Recruiting
Memphis, Tennessee, United States, 38105
Contact: Fariba Navid, MD    866-278-5833    info@stjude.org   
Principal Investigator: Fariba Navid, MD         
Sponsors and Collaborators
St. Jude Children's Research Hospital
University of Tennessee Health Science Center
University of Florida
Nemours Children's Clinic
Investigators
Principal Investigator: Fariba Navid, MD St. Jude Children's Research Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: St. Jude Children's Research Hospital
ClinicalTrials.gov Identifier: NCT01946529     History of Changes
Other Study ID Numbers: ESFT13
Study First Received: September 16, 2013
Last Updated: June 9, 2014
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Additional relevant MeSH terms:
Sarcoma
Sarcoma, Ewing
Desmoplastic Small Round Cell Tumor
Neoplasms
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Neuroectodermal Tumors, Primitive, Peripheral
Neoplasms by Histologic Type
Neoplasms, Bone Tissue
Neoplasms, Connective and Soft Tissue
Neoplasms, Connective Tissue
Neoplasms, Germ Cell and Embryonal
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue
Neoplasms, Neuroepithelial
Osteosarcoma
Bevacizumab
Cyclophosphamide
Doxorubicin
Etoposide
Etoposide phosphate
Everolimus
Ifosfamide
Isophosphamide mustard
Liposomal doxorubicin
Sirolimus
Sorafenib
Temozolomide
Vincristine
Alkylating Agents

ClinicalTrials.gov processed this record on October 22, 2014